Inflammation combined with ischemia produces myelin injury and plaque-like aggregates of myelin, amyloid-β and AβPP in adult rat brain

Journal of Alzheimer's Disease

Volumn 46, Issue 2, 2015, Pages 507-523

  Zhan, Xinhua ^a   Cox, Christopher ^a   Ander, Bradley P ^a   Liu, Dazhi ^a   Stamova, Boryana ^a   Jin, Lee Way ^a,b   Jickling, Glen C ^a   Sharp, Frank R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid plaques; amyloid ; amyloid protein precursor; hypoxia; lipopolysaccharide; myelin; myelin basic protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GRANZYME B; INTERLEUKIN 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

5XFAD MOUSE; ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; BRAIN CORTEX; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; ENCEPHALITIS; GENE MUTATION; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING; WHITE MATTER INJURY; ANIMAL; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; INFLAMMATION; METABOLISM; MYELIN SHEATH; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, TRANSGENIC; MYELIN BASIC PROTEIN; MYELIN SHEATH; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84930460163     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143072     Document Type: Article

References (61)

1. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204
2. Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2, pii: a006239
3. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, KasteM(1998) Clinical determinants of poststroke dementia. Stroke 29, 75-81
4. Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, Tseng CL, Chan S, Williams JB, Remien RH, Hauser WA, Stern Y (2000) Frequency and clinical determinants of dementia after ischemic stroke. Neurology 54, 1124-1131
5. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D (2001) Poststroke dementia: Incidence and relationship to prestroke cognitive decline. Neurology 57, 1216-1222
6. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222
7. Matute C, Domercq M, Perez-Samartin A, Ransom BR (2013) Protecting white matter from stroke injury. Stroke 44, 1204-1211
8. Hijdra A, Verbeeten B Jr, Verhulst JA (1990) Relation of leukoaraiosis to lesion type in stroke patients. Stroke 21, 890-894
9. Leys D, Henon H, Pasquier F (1998) White matter changes and poststroke dementia. Dement Geriatr Cogn Disord 9(Suppl 1), 25-29
10. Liu H, Le W (2014) Epigenetic modifications of chronic hypoxia-mediated neurodegeneration in Alzheimer's disease. Transl Neurodegener 3, 7
11. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG (2006) White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37, 1391-1398
12. Iadecola C (2013) The pathobiology of vascular dementia. Neuron 80, 844-866
13. Rahkonen T, Makela H, Paanila S, Halonen P, Sivenius J, Sulkava R (2000) Delirium in elderly people without severe predisposing disorders: Etiology and 1-year prognosis after discharge. Int Psychogeriatr 12, 473-481
14. Dunn N, Mullee M, Perry VH, Holmes C (2005) Association between dementia and infectious disease: Evidence from a case-control study. Alzheimer Dis Assoc Disord 19, 91-94
15. Verreault R, Laurin D, Lindsay J, De Serres G (2001) Past exposure to vaccines and subsequent risk of Alzheimer's disease. CMAJ 165, 1495-1498
16. Xu H, Stamova B, Jickling G, Tian Y, Zhan X, Ander BP, Liu D, Turner R, Rosand J, Goldstein LB, Furie KL, Verro P, Johnston SC, Sharp FR, Decarli CS (2010) Distinctive RNAexpression profiles in blood associated with white matter hyperintensities in brain. Stroke 41, 2744-2749
17. Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA (2011) The developing oligodendrocyte: Key cellular target in brain injury in the premature infant. Int JDev Neurosci 29, 423-440
18. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T (2002) The toll-like receptor TLR4 is necessary for lipopolysaccharideinduced oligodendrocyte injury in the CNS. J Neurosci 22, 2478-2486
19. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140
20. Zhan X, Kim C, Sharp FR (2008) Very brief focal ischemia simulating transient ischemic attacks (TIAs) can injure brain and induce Hsp70 protein. Brain Res 1234, 183-197
21. Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K (2004) Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem 39, 573-578
22. Liu L, Chan C (2014) The role of inflammasome in Alzheimer's disease. Ageing Res Rev 15C, 6-15
23. Hiebert PR, Granville DJ (2012) Granzyme B in injury, inflammation, and repair. Trends Mol Med 18, 732-741
24. Liao MC, Ahmed M, Smith SO, Van Nostrand WE (2009) Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem 284, 28917-28925
25. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE (2009) Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro. Biochemistry 48, 4720-4727
26. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738
27. Ulevitch RJ (1993) Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv Immunol 53, 267-289
28. Zhou H, Lapointe BM, Clark SR, Zbytnuik L, Kubes P (2006) A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 177, 8103-8110
29. Mun-Bryce S, Rosenberg GA (1998) Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 274, R1203-R1211
30. Sherwin C, FernR(2005) Acute lipopolysaccharide-mediated injury in neonatal white matter glia: Role of TNF-Alpha, IL-1beta, and calcium. J Immunol 175, 155-161
31. Vanguri P, Lee E, Henkart P, Shin ML (1993) Hydrolysis of myelin basic protein in myelin membranes by granzymes of large granular lymphocytes. J Immunol 150, 2431-2439
32. Spaeny-Dekking EH, Kamp AM, Froelich CJ, Hack CE (2000) Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors. Blood 95, 1465-1472
33. Rucevic M, Fast LD, Jay GD, Trespalcios FM, Sucov A, Siryaporn E, Lim YP (2007) Altered levels and molecular forms of granzyme k in plasma from septic patients. Shock 27, 488-493
34. Simi A, Lerouet D, Pinteaux E, Brough D (2007) Mechanisms of regulation for interleukin-1beta in neurodegenerative disease. Neuropharmacology 52, 1563-1569
35. Denes A, Lopez-Castejon G, Brough D. (2012) Caspase-1: Is IL-1 just the tip of the ICEberg?. Cell Death Dis 3, e338
36. Davaro F, Forde SD, Garfield M, Jiang Z, Halmen K, Tamburro ND, Kurt-Jones E, Fitzgerald KA, Golenbock DT, Wang D (2014) 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1beta interferes with mature IL-1beta signaling. J Biol Chem 289, 16214-16222
37. Edye ME, Lopez-Castejon G, Allan SM, Brough D (2013) Acidosis drives damage-Associated molecular pattern (DAMP)-induced interleukin-1 secretion via a caspase-1-independent pathway. J Biol Chem 288, 30485-30494
38. Shamseddine AA, Airola MV, Hannun YA (2015) Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul 57C, 24-41
39. Nikolova-Karakashian M, Karakashian A, Rutkute K (2008) Role of neutral sphingomyelinases in aging and inflammation. Subcell Biochem 49, 469-486
40. Nalivaeva NN, Rybakina EG, Pivanovich I, Kozinets IA, Shanin SN, Bartfai T (2000) Activation of neutral sphingomyelinase by IL-1beta requires the type 1 interleukin 1 receptor. Cytokine 12, 229-232
41. Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licinio J, Tabas I (2000) Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A 97, 8681-8686
42. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, Castaneda J, Gonzalez C, Villamor E, Perez-Vizcaino F (2009) Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 82, 296-302
43. Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J, Duerksen-Hughes PJ (2012) Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis 29, 537-547
44. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S (2007) LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 26, 313-324
45. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V (1998) p75 and TrkA receptor signaling independently regulate amyloid precursor protein mRNA expression, isoform composition, and protein secretion in PC12 cells. J Neurochem 71, 757-766
46. Braak H, Braak E (1997) Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 18, 351-357
47. Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J (2003) White matter structural integrity in healthy aging adults and patients with Alzheimer disease: A magnetic resonance imaging study. Arch Neurol 60, 393-398
48. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL (2004) Heterogeneous age-related breakdown of white matter structural integrity: Implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 25, 843-851
49. Bartzokis G (2011) Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 32, 1341-1371
50. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ (2009) Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57, 54-65
51. Braak H, Del Tredici K, Schultz C, Braak E (2000) Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci 924, 53-61
52. Englund E, Brun A, Alling C (1988) White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 111(Pt 6), 1425-1439
53. Zhan X, Jickling GC, Ander BP, Liu D, Stamova B, Cox C, Jin LW, DeCarli C, Sharp FR (2014) Myelin injury and degraded myelin vesicles in Alzheimer's disease. Curr Alzheimer Res 11, 232-238
54. Zhan X, Jickling GC, Ander BP, Stamova B, Liu DZ, Kao PF, Zelin MA, Jin L-W, DeCarli C, Sharp FR (2015) Myelin basic protein associates with A-PP, A-1-42, and amyloid plaques in cortex of Alzheimer brain. J Alzheimers Dis 44, 1213-1229
55. Upadhaya AR, Lungrin I, Yamaguchi H, Fandrich M, Thal DR (2012) High-molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16, 287-295
56. Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, Cole GM, Gylys KH (2012) AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 33, 1545-1555
57. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14, 133-145
58. Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfield DA, Banks WA (2009) Lipopolysaccharide alters the bloodbrain barrier transport of amyloid beta protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 23, 507-517
59. Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA (2012) Lipopolysaccharide impairs amyloid beta efflux from brain: Altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation 9, 150
60. Li J, Sheng W, Feng C, Zuo Z (2012) Pyrrolidine dithiocarbamate attenuates brain Abeta increase and improves long-term neurological outcome in rats after transient focal brain ischemia. Neurobiol Dis 45, 564-572
61. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG, Meyer R, Rivnak AJ, Pink BA, Minnehan KA, Piech T, Rissin DM, Duffy DC, Rubertsson S, Wilson DH, Blennow K (2011) Hypoxia due to cardiac arrest induces a timedependent increase in serum amyloid beta levels in humans. PLoS One 6, e28263